Bode C, Meinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, kübler W, Haber E (1991)
Platelet targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation
Circulation 84:805-813
Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw S-Y, Huang PL, Chou CC, Mullins D, Schnee JM, Savard CE, Rothemberg ME, Newell JB, Matsueda GR, Haber E (1991)
A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.
Proc Natl Acad Sci USA 88:10337-10341
Bode C, Runge MS, Eberle T, Freitag M, Kübler W, Haber E (1989)
Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody
Trans Assoc Am Phys 102:7-12
Bode C, Bumann H, von Hodenberg E, Freitag M, Nordt T (1993)
Combinations of thrombolytic agents in acute myocardial infarction
Z Kardiol 82: Suppl.2, 125-128
Bode C, Nordt T, Freitag M, Ruef J, Kaltenmeier M, Meinhadt G, Kübler W, Haber E (1991)
Verstärkte Thrombolyse und verminderte Thrombozytenaggregation durch ein anti-GP Iib/IIIa-Antikörper Urokinase Hybridmolekül (7E3-UK) in: Verhandlungen der Deutschen Gesellschaft für Innere Medizin (Preisvortrag) Editor: Mielke K. Springer Verlag Heidelberg, New York, Tokyo, S.1-2
Bode C, Hudelmayer M, Mehwald P, Bauer S, Freitag M, von Hodenberg E, Newell JB, Kübler W, Haber E, Runge MS (1994)
Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin
Circulation 90: 1956-1963